Synthetic Biotics: The Biotherapeutics of The Future | Inscripta
Synthetic biology is a relatively new, but rapidly growing industry, gaining traction in many business sectors across the ever-growing bioeconomy....
Your Favorite Library Series: Library 1: Genome-Wide Knockout (GWKO)
We’re kicking off a series of our favorite “library recipes” to showcase different library designs Inscripta scientists have created using...
The White House Summit on Biotechnology and Biomanufacturing
Author: Sri Kosaraju Last week I was honored to represent Inscripta at the White House Summit on Biotechnology and Biomanufacturing....
Inside Inscripta: Michael Gonzales
Successful marketing for a science company requires a special combination of skills. You need to possess a technical foundation to...
Deep mutational scanning of essential bacterial proteins can guide antibiotic development
It is estimated that nearly 5 million patients who die annually have at least one antimicrobial-resistant infection and these infections...
Inside Inscripta: Alex Hutcheson, Sales
At Inscripta our customers, both current and future, are everything. It takes the right combination of technical expertise and people...
Willow Biosciences Incorporates Inscripta’s Onyx® Platform to Expand its Strain Engineering Capabilities
This week Willow Bioscience, a leading biotech company that produces sustainable, bio-based ingredients, announced they have adopted Inscripta’s Onyx platform...
Aldevron Licenses the Manufacturing of MAD7™ Nuclease from Inscripta
This week we announced a licensing agreement with Aldevron to manufacture and commercialize Inscripta’s proprietary wild-type MAD7 Type-V CRISPR nuclease...
Inside Inscripta: Jamie Schwendinger-Schreck, Applications Development
As we continue to add to the Onyx® platform’s capabilities, we have countless research projects underway here at Inscripta. It...